China’s COVID-19 Vaccination Second Booster Shot Plan Released
The National Health Commission website indicates that the COVID-19 Joint Prevention and Control Mechanism of...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...
Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...
Beijing Releases COVID-19 Infection Drug List to Address Stocking Issues
The Beijing Municipal Health Commission formulated and released the “COVID-19 infection drug list” (first edition),...
Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange
China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...
China’s State Council Boosts Internet Medical Services Amid COVID-19
The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...
Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment
China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...
Yantai Dongcheng to Acquire US Firm XingImaging for $30.2M
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) is set to acquire a 100%...
Hotgen Biotech’s COVID-19 Antigen Home Test Approved in Russia
China-based Hotgen Biotech Co., Ltd (SHA: 688068) announced receiving market approval in Russia for its...
Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting
China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...
ClinBrain and WCH Establish Joint Laboratory for Geriatric Information Platform
Shanghai-based ClinBrain, a clinical data repository (CDR) and medical big data services provider, together with...
Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...
4B Technologies Raises RMB 100M in Pre-Series B Financing Round
China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development,...
Gaush Meditech IPOs on Hong Kong Stock Exchange at HKD 21.4 per Share
China-based Gaush Meditech Ltd reportedly made an initial public offering (IPO) at the Hong Kong...
Northeast Pharmaceutical Fined RMB 133M for Monopoly Selling
Northeast Pharmaceutical Co., Ltd (SHE: 000597) was fined RMB 133 million (USD 19m) by the...